Hunniwell Lake Ventures invests in extensions of proven technologies within overlooked segments of the medical device space from the heart of Silicon Valley.
Our vision is to be the enabler for the emergence of a number of full-line medical device companies that are market leaders in their respective fields.
The SynCardia temporary Total Artificial Heart (TAH-t) is a treatment option for cardiac transplant-eligible patients at risk of imminent death from biventricular failure.
Medical Advice Disclaimer
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE
The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on this website.
